TCR2 THERAPEUTICS INC (TCRR) Stock Price, Quote, News and Overview
NASDAQ:TCRR - Nasdaq - US87808K1060 - Common Stock - Currency: USD
TCRR Quote, Performance and Key Statistics
1.48
-0.09 (-5.73%)
The current stock price of TCRR is 1.48 USD. In the past month the price decreased by -17.32%. In the past year, price decreased by -38.59%.
TCRR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About TCRR
Company Profile
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2019-02-14. The firm's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The firm completed the Phase I portion of its Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510 and TC-520. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor. Its TC-520 is the Company’s TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to improve T-cell persistence.
Company Info
TCR2 THERAPEUTICS INC
100 Binney St
Cambridge MASSACHUSETTS 02142 US
CEO: Garry E. Menzel
Employees: 58
Company Website: https://www.tcr2.com/
Phone: 16179495200.0
TCR2 THERAPEUTICS INC / TCRR FAQ
What is the stock price of TCR2 THERAPEUTICS INC today?
The current stock price of TCRR is 1.48 USD. The price decreased by -5.73% in the last trading session.
What is the ticker symbol for TCR2 THERAPEUTICS INC stock?
The exchange symbol of TCR2 THERAPEUTICS INC is TCRR and it is listed on the Nasdaq exchange.
On which exchange is TCRR stock listed?
TCRR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TCR2 THERAPEUTICS INC stock?
12 analysts have analysed TCRR and the average price target is 5.86 USD. This implies a price increase of 295.87% is expected in the next year compared to the current price of 1.48. Check the TCR2 THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TCR2 THERAPEUTICS INC worth?
TCR2 THERAPEUTICS INC (TCRR) has a market capitalization of 58.11M USD. This makes TCRR a Micro Cap stock.
How many employees does TCR2 THERAPEUTICS INC have?
TCR2 THERAPEUTICS INC (TCRR) currently has 58 employees.
What are the support and resistance levels for TCR2 THERAPEUTICS INC (TCRR) stock?
TCR2 THERAPEUTICS INC (TCRR) has a resistance level at 1.49. Check the full technical report for a detailed analysis of TCRR support and resistance levels.
Should I buy TCR2 THERAPEUTICS INC (TCRR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TCRR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TCRR, evaluating the profitability, health, valuation and growth aspects
- TCR2 THERAPEUTICS INC (TCRR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TCR2 THERAPEUTICS INC (TCRR) Sales and EPS estimates to see what analysts future expectations are.
- TCR2 THERAPEUTICS INC (TCRR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TCR2 THERAPEUTICS INC (TCRR) Insider and Institutional Ownership to learn about the owners and their transactions.
- TCR2 THERAPEUTICS INC (TCRR) Stock Chart to make your own analysis
- TCR2 THERAPEUTICS INC (TCRR) Latest news and press-releases to stay up to date.
Does TCR2 THERAPEUTICS INC (TCRR) stock pay dividends?
TCRR does not pay a dividend.
When does TCR2 THERAPEUTICS INC (TCRR) report earnings?
TCR2 THERAPEUTICS INC (TCRR) will report earnings on 2023-08-07, before the market open.
What is the Price/Earnings (PE) ratio of TCR2 THERAPEUTICS INC (TCRR)?
TCR2 THERAPEUTICS INC (TCRR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.2).
TCRR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TCRR. When comparing the yearly performance of all stocks, TCRR is a bad performer in the overall market: 69.05% of all stocks are doing better.
TCRR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TCRR. TCRR has a bad profitability rating. Also its financial health evaluation is rather negative.
TCRR Financial Highlights
Over the last trailing twelve months TCRR reported a non-GAAP Earnings per Share(EPS) of -4.2. The EPS decreased by -49.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
TCRR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to TCRR. The Buy consensus is the average rating of analysts ratings from 12 analysts.